Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent – Positive Feedback on Phase III Trial Design –

Serac Healthcare today announced positive feedback from its End of Phase II Meeting with the US Food and Drug Administration (FDA) for the development of ^99mTc-maraciclatide as a diagnostic agent for use with single-photon emission computed tomography (SPECT-CT) for the visualisation and diagnosis of superficial peritoneal endometriosis (SPE) in women aged 16 years of age and older.